Quarterly ResultMay 14, 2026, 07:16 AM
Cypherpunk Q1 Net Loss $77.2M; ZEC Holdings Decline
AI Summary
Cypherpunk Technologies reported a net loss of $77.2 million for Q1 2026, significantly wider than the $15.4 million loss in Q1 2025, primarily due to a $77.6 million unrealized loss on its ZEC treasury holdings as the ZEC price declined. Despite this, the company increased its Zcash holdings to 314,185.70 ZEC and made a $5 million investment in Zcash Open Development Labs. Its subsidiary, Leap Therapeutics, received FDA Fast Track designation for sirexatamab and presented positive Phase 2 DeFianCe study results for colorectal cancer.
Key Highlights
- Reported Q1 2026 net loss of $77.2 million, compared to $15.4 million in Q1 2025.
- Incurred a $77.6 million unrealized loss on ZEC treasury holdings due to price decline.
- Increased Zcash treasury holdings to 314,185.70 ZEC, valued at $73.8 million.
- Invested $5 million into Zcash Open Development Labs (ZODL).
- Leap Therapeutics' sirexatamab received FDA Fast Track designation in May 2026.
- DeFianCe study showed 42% ORR and mOS not reached in DKK1-high CRC patients.
- Cash and cash equivalents totaled $6.7 million as of March 31, 2026.
Price Impact
More from CYPH